GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CymaBay Therapeutics Inc (NAS:CBAY) » Definitions » Cyclically Adjusted PB Ratio

CymaBay Therapeutics (CymaBay Therapeutics) Cyclically Adjusted PB Ratio : 16.00 (As of Jun. 04, 2024)


View and export this data going back to 2014. Start your Free Trial

What is CymaBay Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-06-04), CymaBay Therapeutics's current share price is $32.48. CymaBay Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $2.03. CymaBay Therapeutics's Cyclically Adjusted PB Ratio for today is 16.00.

The historical rank and industry rank for CymaBay Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

CBAY' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 5.53   Med: 8.72   Max: 16
Current: 15.98

During the past years, CymaBay Therapeutics's highest Cyclically Adjusted PB Ratio was 16.00. The lowest was 5.53. And the median was 8.72.

CBAY's Cyclically Adjusted PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 1.745 vs CBAY: 15.98

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

CymaBay Therapeutics's adjusted book value per share data for the three months ended in Dec. 2023 was $2.567. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.03 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


CymaBay Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for CymaBay Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CymaBay Therapeutics Cyclically Adjusted PB Ratio Chart

CymaBay Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 3.18 11.62

CymaBay Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.18 4.40 5.53 7.38 11.62

Competitive Comparison of CymaBay Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, CymaBay Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CymaBay Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CymaBay Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where CymaBay Therapeutics's Cyclically Adjusted PB Ratio falls into.



CymaBay Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

CymaBay Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=32.48/2.03
=16.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CymaBay Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, CymaBay Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=2.567/129.4194*129.4194
=2.567

Current CPI (Dec. 2023) = 129.4194.

CymaBay Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201403 1.130 99.695 1.467
201406 0.842 100.560 1.084
201409 1.779 100.428 2.293
201412 0.942 99.070 1.231
201503 1.198 99.621 1.556
201506 1.159 100.684 1.490
201509 1.428 100.392 1.841
201512 1.199 99.792 1.555
201603 0.932 100.470 1.201
201606 0.658 101.688 0.837
201609 0.436 101.861 0.554
201612 0.168 101.863 0.213
201703 0.321 102.862 0.404
201706 0.074 103.349 0.093
201709 1.973 104.136 2.452
201712 1.913 104.011 2.380
201803 3.614 105.290 4.442
201806 3.379 106.317 4.113
201809 3.165 106.507 3.846
201812 2.866 105.998 3.499
201903 3.750 107.251 4.525
201906 3.436 108.070 4.115
201909 3.094 108.329 3.696
201912 2.705 108.420 3.229
202003 2.541 108.902 3.020
202006 2.404 108.767 2.860
202009 2.274 109.815 2.680
202012 2.070 109.897 2.438
202103 1.851 111.754 2.144
202106 1.552 114.631 1.752
202109 1.261 115.734 1.410
202112 1.570 117.630 1.727
202203 1.268 121.301 1.353
202206 0.974 125.017 1.008
202209 0.711 125.227 0.735
202212 0.427 125.222 0.441
202303 1.070 127.348 1.087
202306 1.108 128.729 1.114
202309 2.880 129.860 2.870
202312 2.567 129.419 2.567

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CymaBay Therapeutics  (NAS:CBAY) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


CymaBay Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of CymaBay Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CymaBay Therapeutics (CymaBay Therapeutics) Business Description

Traded in Other Exchanges
Address
7575 Gateway Boulevard, Suite 110, Newark, CA, USA, 94560
CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).
Executives
Charles Mcwherter officer: Chief Scientific Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Daniel Menold officer: Vice President, Finance C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Paul T Quinlan officer: General Counsel C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Janet Dorling director C/O ACHAOGEN, INC., 1 TOWER PLACE, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Sujal Shah director, officer: Chief Executive Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Kurt Von Emster director 601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080
Harish Shantharam officer: Chief Financial Officer 7575 GATEWAY BLVD, NEWARK CA 94560
Dennis D Kim officer: Chief Medical Officer C/O EMERALD BIOSCIENCE, INC., 130 NORTH MARINA DRIVE, LONG BEACH CA 90803
Eric Lefebvre director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Thomas G Wiggans director
Lewis J Stuart officer: Chief Commercial Officer 3172 PORTER DRIVE, PALO ALTO CA 94304
Venbio Select Advisor Llc 10 percent owner 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Behzad Aghazadeh 10 percent owner C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Carl Goldfischer director 161 WEST 61ST STREET, NEW YORK NY 10022
Robert James Wills director 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103

CymaBay Therapeutics (CymaBay Therapeutics) Headlines